Focused on developing therapies for neuropsychiatric and neurological disorders, Mindset Pharma (CSE:MSET/FSE:9DF) has identified three families of next-generation psychedelics. Families 6, 7 and 8 are chemically distinct, small molecule non-tryptamine scaffolds. Tryptamine hallucinogens include LSD, DMT and psilocybin. Mindset Pharma has filed provisional patent applications for the three families. The Toronto-based company had already announced it…